OBJECTIVE: CD44(+)CD24(-/low)-expressing tumor cells have been studied as tumorigenic stem cells in vitro study. This study was designed to determine the clinical implication of the CD44 and CD24 expression in breast cancer. METHODS: Tissue microarray blocks containing 643 consecutive cases of invasive breast carcinomas from 1993 to 1998 were immunostained for CD44 and CD24. The median follow-up period was 127 months. RESULTS: CD44(-)CD24(+) phenotype was associated with frequent hormone receptor positivity and Her2/neu positivity (P = 0.000; Both). The CD44(+)CD24(-) phenotype was inversely associated with lymph node metastasis (P = 0.002), and it showed positive associations with prolonged disease-free survival (DFS; P = 0.003) and overall survival (OS; P = 0.002). 10-year DFS and OS were 68.9% and 74.6% for CD24 negative group, 55.6% and 60.9% for CD24 positive group (P = 0.001; Both). 10-year DFS and OS were 62.2% and 68.1% for CD44 negative group, 73% and 77.7% for CD44 positive group (P = 0.012, P = 0.013, respectively). In a multivariate analysis, CD24 expression was negatively related to OS only in the receptor positive group (Hazard ratio = 2.03; P = 0.003; 95% CI: 1.27-3.24) and CD44 expression was positively related to OS only in the hormone receptor negative group (hazard ratio = 0.58; P = 0.022; 95% CI: 0.36-0.92). CONCLUSIONS: The CD44(+)CD24(-) group is considered a favorable prognostic subgroup in breast cancer. CD24 expression was a poor prognosis marker in hormone receptor positive breast cancer, and CD44 expression was a good prognostic marker in the receptor negative group.
OBJECTIVE:CD44(+)CD24(-/low)-expressing tumor cells have been studied as tumorigenic stem cells in vitro study. This study was designed to determine the clinical implication of the CD44 and CD24 expression in breast cancer. METHODS: Tissue microarray blocks containing 643 consecutive cases of invasive breast carcinomas from 1993 to 1998 were immunostained for CD44 and CD24. The median follow-up period was 127 months. RESULTS:CD44(-)CD24(+) phenotype was associated with frequent hormone receptor positivity and Her2/neu positivity (P = 0.000; Both). The CD44(+)CD24(-) phenotype was inversely associated with lymph node metastasis (P = 0.002), and it showed positive associations with prolonged disease-free survival (DFS; P = 0.003) and overall survival (OS; P = 0.002). 10-year DFS and OS were 68.9% and 74.6% for CD24 negative group, 55.6% and 60.9% for CD24 positive group (P = 0.001; Both). 10-year DFS and OS were 62.2% and 68.1% for CD44 negative group, 73% and 77.7% for CD44 positive group (P = 0.012, P = 0.013, respectively). In a multivariate analysis, CD24 expression was negatively related to OS only in the receptor positive group (Hazard ratio = 2.03; P = 0.003; 95% CI: 1.27-3.24) and CD44 expression was positively related to OS only in the hormone receptor negative group (hazard ratio = 0.58; P = 0.022; 95% CI: 0.36-0.92). CONCLUSIONS: The CD44(+)CD24(-) group is considered a favorable prognostic subgroup in breast cancer. CD24 expression was a poor prognosis marker in hormone receptor positive breast cancer, and CD44 expression was a good prognostic marker in the receptor negative group.
Authors: Agnieszka Adamczyk; Joanna A Niemiec; Aleksandra Ambicka; Anna Mucha-Małecka; Jerzy Mituś; Janusz Ryś Journal: J Mol Histol Date: 2013-07-09 Impact factor: 2.611
Authors: T Dan; S M Hewitt; N Ohri; D Ly; B P Soule; S L Smith; K Matsuda; C Council; U Shankavaram; M E Lippman; J B Mitchell; K Camphausen; N L Simone Journal: Breast Cancer Res Treat Date: 2013-11-26 Impact factor: 4.872
Authors: Anne Grosse-Wilde; Aymeric Fouquier d'Hérouël; Ellie McIntosh; Gökhan Ertaylan; Alexander Skupin; Rolf E Kuestner; Antonio del Sol; Kathie-Anne Walters; Sui Huang Journal: PLoS One Date: 2015-05-28 Impact factor: 3.240
Authors: Mi Jeong Kwon; Jinil Han; Ji Hyun Seo; Kyoung Song; Hae Min Jeong; Jong-Sun Choi; Yu Jin Kim; Seon-Heui Lee; Yoon-La Choi; Young Kee Shin Journal: PLoS One Date: 2015-10-07 Impact factor: 3.240